Candriam S.C.A. Lowers Stock Holdings in Hologic, Inc. $HOLX

Key Points

• Candriam S.C.A. significantly reduced its holdings in Hologic, Inc. by 54.5%, selling 514,191 shares and owning a total of 430,141 shares post-sale.
• A variety of institutional investors have modified their positions in Hologic, with total institutional ownership now at 94.73%.
• Market analysts have provided mixed ratings for Hologic, with a consensus average rating of "Moderate Buy" and target prices ranging from $62.00 to $78.00.

Candriam S.C.A. reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 54.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 430,141 shares of the medical equipment provider's stock after selling 514,191 shares during the quarter. Candriam S.C.A. owned approximately 0.19% of Hologic worth $26,570,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in HOLX. Victory Capital Management Inc. boosted its position in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after acquiring an additional 1,692,177 shares in the last quarter. Nuance Investments LLC boosted its position in shares of Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after acquiring an additional 931,920 shares in the last quarter. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic during the 1st quarter worth about $3,534,000. Invesco Ltd. lifted its holdings in shares of Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after purchasing an additional 764,573 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on HOLX shares. Raymond James Financial reissued an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Wall Street Zen raised Hologic from a "hold" rating to a "buy" rating in a research note on Friday. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Monday, August 18th. Finally, Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Price Performance

NASDAQ:HOLX traded up $1.09 during trading hours on Friday, reaching $68.26. 1,545,907 shares of the company traded hands, compared to its average volume of 1,851,908. The firm's 50-day moving average is $65.90 and its 200-day moving average is $62.42. The stock has a market cap of $15.18 billion, a P/E ratio of 28.32, a P/E/G ratio of 2.48 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.